The Chemokine Receptor CXCR3 is Expressed on Malignant B Cells and Mediates Chemotaxis

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1999 Jul 7

PMID 10393705

Citations 37

Authors

L Trentin

C Agostini

M Facco

F Piazza

A Perin

M Siviero

C Gurrieri

S Galvan

F Adami

R Zambello

G Semenzato

Affiliations

Soon will be listed here.

Abstract

B- and T-cell recirculation is crucial for the function of the immune system, with the control of cell migration being mainly mediated by several chemokines and their receptors. In this study, we investigated the expression and function of CXCR3 on normal and malignant B cells from 65 patients with chronic lymphoproliferative disorders (CLDs). Although CXCR3 is lacking on CD5(+) and CD5(-) B cells from healthy subjects, it is expressed on leukemic B lymphocytes from all (31/31) patients with chronic lymphocytic leukemia (CLL). The presence of CXCR3 was heterogeneous in other B-cell disorders, being expressed in 2 of 7 patients with mantle cell lymphoma (MCL), 4 of 12 patients with hairy cell leukemia (HCL), and 11 of 15 patients with other subtypes of non-Hodgkin's lymphomas (NHLs). Chemotaxis assay shows that normal B cells from healthy subjects do not migrate in response to IFN-inducible protein 10 (IP-10) and IFN-gamma-induced monokine (Mig). In contrast, a definite migration in response to IP-10 and Mig has been observed in all malignant B cells from patients with CLL, but not in patients with HCL or MCL (1/7 cases tested). Neoplastic B cells from other NHLs showed a heterogenous pattern. The migration elicited by IP-10 and Mig was inhibited by blocking CXCR3. No effect of IP-10 and Mig chemokines was observed on the cytosolic calcium concentration in malignant B cells. The data reported here demonstrate that CXCR3 is expressed on malignant B cells from CLDs, particularly in patients with CLL, and represents a fully functional receptor involved in chemotaxis of malignant B lymphocytes.

Citing Articles

Chemo-Click: Receptor-Controlled and Bioorthogonal Chemokine Ligation for Real-Time Imaging of Drug-Resistant Leukemic B Cells.

Bertolini M, Mendive-Tapia L, Karmakar U, Vendrell M J Am Chem Soc. 2024; 146(44):30565-30572.

PMID: 39441736 PMC: 11544607. DOI: 10.1021/jacs.4c12035.

Clinical and Immunologic Correlates of Vasodilatory Shock Among Ebola Virus-Infected Nonhuman Primates in a Critical Care Model.

Stein S, Platt A, Teague H, Anthony S, Reeder R, Cooper K J Infect Dis. 2023; 228(Suppl 7):S635-S647.

PMID: 37652048 PMC: 10651209. DOI: 10.1093/infdis/jiad374.

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma.

Saber M J Immunol Res. 2023; 2023:4556586.

PMID: 36726488 PMC: 9886470. DOI: 10.1155/2023/4556586.

Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer.

Ahmadzadeh M, Mohit E Biotechnol Lett. 2023; 45(3):371-385.

PMID: 36650341 DOI: 10.1007/s10529-022-03342-y.

Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.

Uhl B, Prochazka K, Pansy K, Wenzl K, Strobl J, Baumgartner C Int J Mol Sci. 2022; 23(14).

PMID: 35887224 PMC: 9316992. DOI: 10.3390/ijms23147874.

References

Luster A . Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338(7):436-45. DOI: 10.1056/NEJM199802123380706. View

Yoshie O, Imai T, Nomiyama H . Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol. 1997; 62(5):634-44. DOI: 10.1002/jlb.62.5.634. View

Sallusto F, Lenig D, Mackay C, Lanzavecchia A . Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998; 187(6):875-83. PMC: 2212187. DOI: 10.1084/jem.187.6.875. View

Piali L, Weber C, Larosa G, Mackay C, Springer T, Clark-Lewis I . The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 1998; 28(3):961-72. DOI: 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4. View

Baggiolini M . Chemokines and leukocyte traffic. Nature. 1998; 392(6676):565-8. DOI: 10.1038/33340. View

Cole K, Strick C, Paradis T, Ogborne K, Loetscher M, Gladue R . Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998; 187(12):2009-21. PMC: 2212354. DOI: 10.1084/jem.187.12.2009. View

Nelson P, Krensky A . Chemokines, lymphocytes and viruses: what goes around, comes around. Curr Opin Immunol. 1998; 10(3):265-70. DOI: 10.1016/s0952-7915(98)80164-7. View

Weng Y, Siciliano S, Waldburger K, Staruch M, Daugherty B, Gould S . Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998; 273(29):18288-91. DOI: 10.1074/jbc.273.29.18288. View

Semenzato G . Chemotactic cytokines: from the molecular level to clinical use. Sarcoidosis Vasc Diffuse Lung Dis. 1998; 15(2):131-3. View

10.

Loetscher M, Loetscher P, Brass N, Meese E, Moser B . Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol. 1998; 28(11):3696-705. DOI: 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W. View

11.

Kim C, Broxmeyer H . Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol. 1999; 65(1):6-15. DOI: 10.1002/jlb.65.1.6. View

12.

Rabin R, Park M, Liao F, Swofford R, Stephany D, Farber J . Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol. 1999; 162(7):3840-50. View

13.

Rai K, SAWITSKY A, CRONKITE E, CHANANA A, Levy R, Pasternack B . Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2):219-34. View

14.

Grynkiewicz G, Poenie M, Tsien R . A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985; 260(6):3440-50. View

15.

Di Virgilio F, Steinberg T, Swanson J, Silverstein S . Fura-2 secretion and sequestration in macrophages. A blocker of organic anion transport reveals that these processes occur via a membrane transport system for organic anions. J Immunol. 1988; 140(3):915-20. View

16.

Trentin L, Zambello R, Agostini C, Ambrosetti A, Chisesi T, Raimondi R . Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia. Blood. 1990; 75(7):1525-30. View

17.

Trentin L, Zambello R, Benati C, Cassatella M, Agostini C, Bulian P . Expression and functional role of the p75 interleukin 2 receptor chain on leukemic hairy cells. Cancer Res. 1992; 52(19):5223-8. View

18.

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

19.

Farace F, Orlanducci F, Dietrich P, Gaudin C, Angevin E, Courtier M . T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol. 1994; 153(9):4281-90. View

20.

Trentin L, Zambello R, Agostini C, Enthammer C, Cerutti A, Adami F . Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood. 1994; 84(12):4249-56. View